Haematologica
(Feb 2019)
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy
- Toby A. Eyre,
- Harriet S. Walter,
- Sunil Iyengar,
- George Follows,
- Matthew Cross,
- Christopher P. Fox,
- Andrew Hodson,
- Josh Coats,
- Santosh Narat,
- Nick Morley,
- Martin J.S. Dyer,
- Graham P. Collins
Affiliations
- Toby A. Eyre
- Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
- Harriet S. Walter
- The Ernest and Helen Scott Haematological Research Institute, University of Leicester
- Sunil Iyengar
- Department of Haematology, The Royal Marsden Hospital, London
- George Follows
- Department of Haematology, Addenbrooke’s Hospital NHS Trust, Cambridge
- Matthew Cross
- Department of Haematology, The Royal Marsden Hospital, London
- Christopher P. Fox
- Department of Haematology, Nottingham University Hospitals NHS Trust
- Andrew Hodson
- Department of Haematology, Ipswich Hospital
- Josh Coats
- Department of Haematology, NHS Tayside, Dundee
- Santosh Narat
- Department of Haematology, Western Sussex Hospitals NHS Foundation Trust, Worthing
- Nick Morley
- Department of Haematology, Ipswich Hospital
- Martin J.S. Dyer
- The Ernest and Helen Scott Haematological Research Institute, University of Leicester
- Graham P. Collins
- Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
- DOI
-
https://doi.org/10.3324/haematol.2018.198812
- Journal volume & issue
-
Vol. 104,
no. 2
WeChat QR code
